Literature DB >> 26706456

Anti-hypersensitive effect of intramuscular administration of αO-conotoxin GeXIVA[1,2] and GeXIVA[1,4] in rats of neuropathic pain.

Xiaodan Li1, Yuanyan Hu2, Yong Wu3, Yi Huang4, Shurun Yu5, Qing Ding6, Dongting Zhangsun7, Sulan Luo8.   

Abstract

αO-conotoxin GeXIVA (GeXIVA) is a potent antagonist of α9α10 nicotinic acetylcholine receptors (nAChRs), which has four Cys residues and three disulfide isomers. Among the 3 isomers, both GeXIVA[1,2] (bead isomer) and GeXIVA[1,4] (ribbon isomer) showed potent block on α9α10 nAChRs with close low nanomolar IC50s. Here we report that anti-hypersensitive effects of the bead and ribbon isomers in the chronic constriction injury (CCI) model of neuropathic pain and acute pain model of tail flick test. Treatment was started and continued for 7 or 14days after the development of hyperalgesia which was induced by CCI surgery. GeXIVA[1,2] and GeXIVA[1,4] significantly reduced mechanical allodynia in CCI rats without tolerance, in which GeXIVA[1,2] remained up to two weeks after intramuscular administration of the toxins was ceased. The pain reliever effect of GeXIVA[1,2] on neuropathic rats was slightly better than GeXIVA[1,4]. The two isomers did not suppress the acute thermal pain behaviors significantly when they were tested in the tail flick model by intramuscular bolus injection. Both GeXIVA[1,2] and GeXIVA[1,4] had no significant effect on performance of rats in the accelerating rotarod test after intramuscular injections. This suggests that αO-conotoxin GeXIVA[1,2] and GeXIVA[1,4] may offer new strategies to the treatment of neuropathic pain.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mechanical hyperalgesia; Neuropathic pain; Thermal pain; αO-Conotoxin GeXIVA[1,2]; αO-Conotoxin GeXIVA[1,4]

Mesh:

Substances:

Year:  2015        PMID: 26706456     DOI: 10.1016/j.pnpbp.2015.12.005

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  14 in total

1.  Critical residue properties for potency and selectivity of α-Conotoxin RgIA towards α9α10 nicotinic acetylcholine receptors.

Authors:  Peter N Huynh; Peta J Harvey; Joanna Gajewiak; David J Craik; J Michael McIntosh
Journal:  Biochem Pharmacol       Date:  2020-06-25       Impact factor: 5.858

2.  Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways.

Authors:  Helena Safavi-Hemami; Shane E Brogan; Baldomero M Olivera
Journal:  J Proteomics       Date:  2018-05-16       Impact factor: 4.044

Review 3.  α9-containing nicotinic acetylcholine receptors and the modulation of pain.

Authors:  Arik J Hone; Denis Servent; J Michael McIntosh
Journal:  Br J Pharmacol       Date:  2017-07-30       Impact factor: 8.739

4.  Backbone cyclization of analgesic conotoxin GeXIVA facilitates direct folding of the ribbon isomer.

Authors:  Xiaosa Wu; Yen-Hua Huang; Quentin Kaas; Peta J Harvey; Conan K Wang; Han-Shen Tae; David J Adams; David J Craik
Journal:  J Biol Chem       Date:  2017-08-28       Impact factor: 5.157

Review 5.  Nicotinic acetylcholine receptors in neuropathic and inflammatory pain.

Authors:  Arik J Hone; J Michael McIntosh
Journal:  FEBS Lett       Date:  2017-10-27       Impact factor: 4.124

6.  αO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human α9α10 subtype.

Authors:  Dongting Zhangsun; Xiaopeng Zhu; Quentin Kaas; Yong Wu; David J Craik; J Michael McIntosh; Sulan Luo
Journal:  Neuropharmacology       Date:  2017-04-14       Impact factor: 5.250

7.  The α9α10 nicotinic acetylcholine receptors antagonist α-conotoxin RgIA reverses colitis signs in murine dextran sodium sulfate model.

Authors:  Shakir D AlSharari; Wisam Toma; Hafiz M Mahmood; J Michael McIntosh; M Imad Damaj
Journal:  Eur J Pharmacol       Date:  2020-07-07       Impact factor: 5.195

8.  RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia.

Authors:  Sean B Christensen; Arik J Hone; Isabelle Roux; Julie Kniazeff; Jean-Philippe Pin; Grégory Upert; Denis Servent; Elisabeth Glowatzki; J Michael McIntosh
Journal:  Front Cell Neurosci       Date:  2017-07-21       Impact factor: 5.505

9.  αO-Conotoxin GeXIVA Inhibits the Growth of Breast Cancer Cells via Interaction with α9 Nicotine Acetylcholine Receptors.

Authors:  Zhihua Sun; Jiaolin Bao; Manqi Zhangsun; Shuai Dong; Dongting Zhangsun; Sulan Luo
Journal:  Mar Drugs       Date:  2020-04-07       Impact factor: 5.118

10.  Antinociceptive Effects of Prim-O-Glucosylcimifugin in Inflammatory Nociception via Reducing Spinal COX-2.

Authors:  Liu-Qing Wu; Yu Li; Yuan-Yan Li; Shi-Hao Xu; Zong-Yong Yang; Zheng Lin; Jun Li
Journal:  Biomol Ther (Seoul)       Date:  2016-05-31       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.